BioSpace News Archive

Syneos Health® announced it is introducing a dedicated HUB Patient Suite combining the Company’s advisory, analytics and digitally-enabled capabilities to bring modern, prescription management services to Syneos Health Deployment Solutions customers.

HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a Phase II/III trial of fruquintinib in combination with sintilimab as second-line treatment for locally advanced or metastatic renal cell carcinoma (“RCC”) in China.

Trevi Therapeutics, Inc. today announced data from the full set of subjects from CANAL, a phase 2 trial in idiopathic pulmonary fibrosis (IPF) chronic cough, will be presented as an oral presentation at the upcoming British Thoracic Society’s (BTS) Winter Meeting 2022 taking place in London, United Kingdom.

Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results for the third quarter ended September 30, 2022 and provided a business update.

Endo International plc (OTC: ENDPQ) and the Sexual Medicine Society of North America (SMSNA) announced today the launch of a Peyronie’s Self-Assessment application, available now in the App Store and Google Play.

Soligenix, Inc. announced today that the Company has been invited by the Biomedical Advanced Research and Development Authority (BARDA) Division of Chemical, Biological, Radiological and Nuclear (CBRN) Medical Countermeasures to submit a full contract proposal for the development of single-vial, adjuvanted, heat stable subunit vaccines to prevent filovirus infection.

Invitae (NYSE: NVTA), a leading medical genetics company, today announced a partnership with AstraZeneca (LSE/STO/Nasdaq: AZN) to use Invitae’s Ciitizen natural history data in a retrospective and prospective study of patients diagnosed with cholangiocarcinoma, a rare bile duct cancer.

Better Therapeutics, Inc. announced today that Diane Gomez-Thinnes joined the company as Chief Commercial Officer.

Cresilon, Inc. announced the successful completion of a $25 million Series A-4 financing round.

Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) (“Isofol”), will publish the company’s results for the third quarter of 2022 on Friday, November 11, 2022.